Jazz Pharmaceuticals
NASDAQ:JAZZBiotechDublin, Ireland, Ireland · Est. 2003 · 2,600 employees
Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines in the fields of neurology, psychiatry, sleep medicine, and oncology.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
200
Clinical Trials↗
All sponsored trials (all statuses)
83
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Phase 31
Phase 23
Phase 13
By Therapeutic Area
top 2
Oncology
233%
Neurology
233%
R&D Momentum
55/100
Pipeline Velocity
25/100
Trial Completion Rate
77/100
Pipeline Concentration
33/100
Pipeline Freshness
77/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Oncology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Recruiting
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Jul 3, 2026
Recruiting
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Jul 2, 2026
Completed
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Jul 1, 2026
Active, not recruiting
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Earlier
Jun 30, 2026TrialA Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jun 30, 2026TrialObservational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant
Apr 25, 2026TrialA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Feb 24, 2026EX-99.1Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
4 more events
Feb 3, 2026TrialA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
Jan 2, 2026TrialStudy of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Nov 26, 2025TrialA Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
May 13, 2025TrialA Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
Details
Company Info
Company Overview
$6.5B
Mkt Cap
$376.1M
Revenue
$2.4B
Cash
CEOBruce Cozadd
Founded2003
Employees2,600
HQDublin, Ireland, Ireland
ExchangeNASDAQ:JAZZ
Websitejazzpharmaceuticals.com
LinkedInCompany Page
Therapeutic Focus
OtherNeurologyOncologyNephrologyImmunologyInfectious DiseaseCardiovascularGastroenterologyHematologyRespiratoryPsychiatryMusculoskeletalMetabolic & EndocrineDermatology
Recent SEC Filings
EX-99.1Feb 24, 2026
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Unknown / Other
Neurology
Focal-Onset Seizure
CBD-OSPhase 1
Narcolepsy
JZP441Phase 1
Oncology
Endometrial Cancer
ModeysoPhase 2
Glioblastoma
ModeysoPhase 2
Unknown / Other
Paraganglioma
ONC206Phase 2
ONC206: Dose 1Phase 2
Regulatory
Regulatory Timeline
20021 event
FDAJul 17
Lumryz — XYREM
Application NDA021196 (NDA)
20161 event
FDAMar 30
Defitelio — DEFITELIO
Application NDA208114 (NDA)
20181 event
FDASep 28
Epidiolex — EPIDIOLEX
Application NDA210365 (NDA)
20201 event
FDAJun 15
Zepzelca — ZEPZELCA
Application NDA213702 (NDA)
20211 event
FDAJun 30
Rylaze — RYLAZE
Application BLA761179 (BLA)
20231 event
FDAMay 1
Lumryz — LUMRYZ
Application NDA214755 (NDA)
20261 event
SECFeb 24
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Accession: 001-33500
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)